Scharf Investments LLC Sells 5,994 Shares of Kenvue Inc. (NYSE:KVUE)

Scharf Investments LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 32.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,353 shares of the company’s stock after selling 5,994 shares during the period. Scharf Investments LLC’s holdings in Kenvue were worth $265,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in KVUE. Beaumont Financial Advisors LLC raised its position in Kenvue by 3.0% during the 4th quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock valued at $377,000 after purchasing an additional 509 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in shares of Kenvue by 51.3% in the 4th quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after buying an additional 526 shares during the last quarter. Tradition Wealth Management LLC grew its stake in shares of Kenvue by 2.8% in the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after buying an additional 575 shares during the last quarter. Dfpg Investments LLC grew its stake in shares of Kenvue by 2.3% in the 4th quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock worth $567,000 after buying an additional 589 shares during the last quarter. Finally, Mutual Advisors LLC grew its stake in shares of Kenvue by 6.1% in the 4th quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock worth $228,000 after buying an additional 612 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.9 %

KVUE traded down $0.17 on Thursday, hitting $18.42. The company had a trading volume of 18,526,877 shares, compared to its average volume of 19,298,117. The company has a market cap of $35.27 billion and a PE ratio of 23.62. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $26.66. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The business’s fifty day simple moving average is $19.22 and its 200 day simple moving average is $20.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.03. The business had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The business’s revenue was down 24.9% on a year-over-year basis. Equities research analysts expect that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 4.34%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s payout ratio is currently 102.56%.

Analyst Ratings Changes

Several analysts recently weighed in on KVUE shares. HSBC upped their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. William Blair began coverage on Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Sanford C. Bernstein assumed coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. Finally, Citigroup reiterated a “neutral” rating and issued a $21.00 price target on shares of Kenvue in a research note on Tuesday, May 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.